HUMULIN N (insulin human) by Eli Lilly and Company. Approved for insulin [epc]. First approved in 1982.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
HUMULIN N is a human insulin product administered via injection for the treatment of diabetes mellitus. It is a basal (intermediate-acting) insulin formulation that helps regulate blood glucose levels in patients who require insulin therapy. The drug works by mimicking the body's natural insulin to facilitate glucose uptake and metabolism.
Market leadership in basal insulin segment with significant Medicare spending, but approaching loss of exclusivity signals transition from growth to defensive strategy and potential team restructuring.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
Worked on HUMULIN N at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on HUMULIN N offers stability in a mature, high-volume franchise, but limited growth opportunity given LOE approaching status and zero linked job postings. Career advancement on this product is constrained; professionals should prioritize roles in market access, reimbursement, and cost management, or transition to newer insulins or non-insulin therapies.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo